Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of April 2014. The document serves as a Notice to Shareholders regarding the Annual General Meeting scheduled for April 30, 2014. The filing primarily addresses corrections to the Proxy Statement and updates to proxy submission deadlines.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation corrections:
- CEO Salary (Dror Ben-Asher): Increased to NIS 75,000 per month (approximately $21,502 USD).
- Executive Salary (Ori Shilo): Increased to NIS 61,400 per month (approximately $17,603 USD).
Exchange rates used for conversion are based on March 24, 2014.
Material Changes
The filing corrects two typographical errors in the previously issued Proxy Statement regarding the U.S. dollar equivalents of New Israeli Shekel (NIS) amounts for executive salaries. Additionally, the deadline for returning proxy cards has been extended:
- ADS Holders: Deadline extended to 12:00 p.m. EST on April 28, 2014 (previously April 25).
- Israeli Shareholders: Deadline extended to 19:00 Israel time on April 28, 2014 (previously 10:00 Israel time).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are discussed beyond the administrative corrections to the meeting materials.
Investor Verification Checklist
- Verify the corrected salary figures for Dror Ben-Asher and Ori Shilo in the updated Proxy Statement.
- Confirm the new proxy submission deadline of April 28, 2014, for both ADS holders and Israeli shareholders.
- Note that this filing does not contain operational or financial performance data for the period.